RXRX
Price
$3.25
Change
+$0.09 (+2.85%)
Updated
Jun 24, 04:59 PM (EDT)
Capitalization
1.72B
48 days until earnings call
Intraday BUY SELL Signals
SANA
Price
$3.30
Change
-$0.05 (-1.49%)
Updated
Jun 24, 04:59 PM (EDT)
Capitalization
912.8M
36 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

RXRX vs SANA

RXRX vs SANA Comparison Chart in %
View a ticker or compare two or three
VS
RXRX vs. SANA commentary
Jun 25, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RXRX is a Hold and SANA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 25, 2026
Stock price -- (RXRX: $3.16 vs. SANA: $3.35)
Brand notoriety: RXRX and SANA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RXRX: 64% vs. SANA: 73%
Market capitalization -- RXRX: $1.68B vs. SANA: $912.8M
RXRX [@Biotechnology] is valued at $1.68B. SANA’s [@Biotechnology] market capitalization is $912.8M. The market cap for tickers in the [@Biotechnology] industry ranges from $118.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.02B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RXRX’s FA Score shows that 1 FA rating(s) are green whileSANA’s FA Score has 0 green FA rating(s).

  • RXRX’s FA Score: 1 green, 4 red.
  • SANA’s FA Score: 0 green, 5 red.
According to our system of comparison, SANA is a better buy in the long-term than RXRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RXRX’s TA Score shows that 2 TA indicator(s) are bullish while SANA’s TA Score has 5 bullish TA indicator(s).

  • RXRX’s TA Score: 2 bullish, 8 bearish.
  • SANA’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, SANA is a better buy in the short-term than RXRX.

Price Growth

RXRX (@Biotechnology) experienced а -0.63% price change this week, while SANA (@Biotechnology) price change was +18.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.44%. For the same industry, the average monthly price growth was +2.06%, and the average quarterly price growth was +1929.02%.

Reported Earning Dates

RXRX is expected to report earnings on Aug 11, 2026.

SANA is expected to report earnings on Jul 30, 2026.

Industries' Descriptions

@Biotechnology (+3.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($1.73B) has a higher market cap than SANA($913M). SANA YTD gains are higher at: -17.690 vs. RXRX (-22.738). SANA has higher annual earnings (EBITDA): -192.2M vs. RXRX (-478.66M). RXRX has more cash in the bank: 654M vs. SANA (101M). RXRX (72.4M) and SANA (75.3M) have identical debt. RXRX has higher revenues than SANA: RXRX (65.7M) vs SANA (0).
RXRXSANARXRX / SANA
Capitalization1.73B913M189%
EBITDA-478.66M-192.2M249%
Gain YTD-22.738-17.690129%
P/E RatioN/AN/A-
Revenue65.7M0-
Total Cash654M101M648%
Total Debt72.4M75.3M96%
TECHNICAL ANALYSIS
Technical Analysis
RXRXSANA
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 13 days ago
83%
Bullish Trend 3 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 13 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
RXRX
Daily Signal:
Gain/Loss:
SANA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CEMVX20.10N/A
N/A
Causeway Emerging Markets Investor
GIEZX17.18N/A
N/A
GuideStone Funds International Eq Inv
CMCRX50.91N/A
N/A
Calvert US Mid Cap Core Rspnb Idx R6
GGWPX14.28N/A
N/A
Goldman Sachs Global Infras P
RMFCX62.22-0.09
-0.14%
American Funds American Mutual R3

RXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXRX has been loosely correlated with ABCL. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if RXRX jumps, then ABCL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXRX
1D Price
Change %
RXRX100%
-0.63%
ABCL - RXRX
60%
Loosely correlated
-1.92%
ABSI - RXRX
60%
Loosely correlated
-12.14%
CRSP - RXRX
59%
Loosely correlated
-0.68%
PRME - RXRX
58%
Loosely correlated
-4.15%
BEAM - RXRX
56%
Loosely correlated
-6.56%
More